Eri Matsuki

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

Takashi Kumagai, Eri Matsuki, Koiti Inokuchi et al. · International Journal of Hematology · 2013 · 24 citations

Medicine, Hematology, Oncology +9

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia

Masatoshi Sakurai, Taku Kikuchi, Daiki Karigane et al. · International Journal of Hematology · 2019 · 24 citations

Medicine, Hematology, Nephrology +15

Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab

Eri Matsuki, Olga L. Bohn, Siraj M. El Jamal et al. · Applied immunohistochemistry & molecular morphology · 2018 · 20 citations · Full text

Medicine, Hematology, Pathology +17

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients

Maiko Matsushita, Kyoko Ozawa, Takaya Suzuki et al. · Blood Cancer Journal · 2017 · 15 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Eri Matsuki, Yukako Ono, Koharu Tonegawa et al. · Blood · 2012 · 13 citations

Medicine, Pharmacology, Pharmacotherapy +6